Iktos
El Gasser Abderraouf has a diverse work experience spanning multiple companies and roles. El Gasser is currently working at Iktos as the Head of Platform Development since June 2022. Prior to this, they held the position of Manager, Software Platform Development at Iktos from July 2020 to June 2022.
Before joining Iktos, El Gasser worked at Trackforce as the VP Engineering from November 2017 to August 2019. El Gasser also served as the Lead Developer at Trackforce from July 2013 to November 2017.
El Gasser started their career at Alphasystem as an Ingénieur logiciels in April 2004 and worked there until March 2012. El Gasser then joined ID's RFQ-hub as an Ingénieur logiciels from April 2012 to June 2013.
Overall, El Gasser Abderraouf has gained significant experience in software development, platform management, and leadership roles throughout their career.
El Gasser Abderraouf completed their education history as follows:
From 2001 to 2004, they attended Pierre and Marie Curie University, where they obtained a Master's degree in Computer Science.
In 2003 and 2004, they pursued further studies at the same university, specializing in Génie des Logiciels Applicatifs (GLA) and earning a postgraduate degree.
Additionally, in December 2022, they obtained a certification as an AWS Certified Solutions Architect – Associate from Amazon Web Services (AWS).
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.